APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 281 filers reported holding APELLIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.61 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $460,284 | -61.2% | 12,100 | -7.2% | 0.00% | -50.0% |
| Q2 2023 | $1,187,580 | +57.8% | 13,036 | +14.2% | 0.00% | +100.0% |
| Q1 2023 | $752,736 | +27.5% | 11,412 | -0.1% | 0.00% | 0.0% |
| Q4 2022 | $590,425 | -26.0% | 11,418 | -2.2% | 0.00% | -50.0% |
| Q3 2022 | $798,000 | +32.1% | 11,680 | -12.5% | 0.00% | +100.0% |
| Q2 2022 | $604,000 | -19.0% | 13,347 | -9.1% | 0.00% | 0.0% |
| Q1 2022 | $746,000 | -39.5% | 14,676 | -43.7% | 0.00% | -50.0% |
| Q4 2021 | $1,233,000 | +131.8% | 26,074 | +61.6% | 0.00% | +100.0% |
| Q3 2021 | $532,000 | -37.3% | 16,136 | +20.2% | 0.00% | -50.0% |
| Q2 2021 | $848,000 | -22.8% | 13,422 | -47.5% | 0.00% | 0.0% |
| Q1 2021 | $1,098,000 | -17.6% | 25,588 | +9.9% | 0.00% | -33.3% |
| Q4 2020 | $1,332,000 | +348.5% | 23,286 | +136.3% | 0.00% | +200.0% |
| Q3 2020 | $297,000 | +10.8% | 9,856 | +20.2% | 0.00% | 0.0% |
| Q2 2020 | $268,000 | – | 8,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |